Navigation Links
Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
Date:12/11/2008

CARY, N.C., Dec. 11 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today provided an update on the status of its integration activities following the closing of the business combination of Critical Therapeutics, Inc. and Cornerstone BioPharma Holdings, Inc. on October 31, 2008, and the renaming of the combined company as Cornerstone Therapeutics Inc. (the Company).

Following the October 31, 2008 closing, the Company has been taking action to effectively and efficiently combine the operations of the two companies. In completing the integration, the Company has achieved a number of key milestones:

  • The Company has discontinued all former Critical Therapeutics research projects and completed a review of those research projects to identify promising technologies suitable for outlicensing to third parties. As a result of this review, the Company has initiated a process to seek potential licensees for certain technologies, including the alpha 7 mediated anti-inflammatory pathway program.
  • The Company completed a restructuring of former Critical Therapeutics officers and employees that resulted in Scott Townsend, General Counsel and Executive Vice President of Legal Affairs, and 12 former Critical Therapeutics sales representatives remaining with Cornerstone.
  • The former Critical Therapeutics facility in Lexington, MA has been vacated and the sublease terminated.

Aggregate revenues from the Company's products have continued to be strong in the fourth quarter. The Company anticipates 2008 net revenues to be in excess of $64 million, which will include revenues attributable to ZYFL
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... a new microscopy technology that allows them to ... resolution. , Dubbed "Complementation Activated Light Microscopy" (CALM), ... an order of magnitude finer than conventional optical ... biomolecules at the nanometer scale. , In a ... Communications , the researchers behind CALM used it ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... the latest addition to Clinovo’s CRO Partnership Program. With ... Program, Clinovo further expands its global reach to Latin ... we are now able to build studies on our ... also rely on Clinovo to fully support the solution ...
(Date:9/18/2014)... Whitehouse Laboratories is pleased to announce that ... has acquired an additional 4,000 square feet of dedicated ... adjacent to its current package testing facility. The official ... Whitehouse Labs is in the process of upgrading the ... testing. The prime location enables Whitehouse Labs to immediately ...
(Date:9/17/2014)... LONDON , Sept. 17, 2014 The global ... Tons by 2019. Squalene is a natural skin-identical chemical that ... & personal care, food supplements, pharmaceuticals, and in other applications ... The squalene market has a few major players and is ... (U.S.), Kishimoto Special Liver Oil Co. Ltd. ( Japan ...
Breaking Biology Technology:Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3
... an effort to spur entrepreneurship in a broader range ... has named the University of Wisconsin-Madison as ... has received $5 million to help train students in ... in 2004 to bring entrepreneurship education to a wider ...
... to provide end-to-end approach to retail workforce optimization ... and the Denver-based StorePerform Technologies, Inc. , ,The ... in the next 20 to 30 days. Financial terms were ... part of RedPrairie's retail productivity division, previously known as ...
... this is my last article of the year, and I have ... my New Year's resolution for this column is bring back more ... is that I simply have not gone to as many concerts ... will need to remedy!) , ,Looking over 2006, my focus has ...
Cached Biology Technology:UW gets $5M to extend entrepreneurship 22006: A great biotech financing year, unless you were going public! 22006: A great biotech financing year, unless you were going public! 32006: A great biotech financing year, unless you were going public! 42006: A great biotech financing year, unless you were going public! 5
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
(Date:9/17/2014)... Copenhagen Centre for Social Evolution and Yale University offers ... weight and -length can partially predict the likelihood of ... and schizophrenia later in life. The study analyzed medical ... diagnoses for up to 30 years, and adjusted for ... published today in the Proceedings of the Royal ...
(Date:9/17/2014)... EAST LANSING, Mich. Mutations in the human retinoblastoma ... Now, Michigan State University scientists have turned to fruit ... cancer gene. , In a paper featured on ... Journal of Biological Chemistry , Michigan State University researchers ... mutations similar to those present in the human cancer ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Abnormal properties of cancer protein revealed in fly eyes 2
... , This news release is available in ... diseases like Parkinson,s disease involve the death of thousands of neurons ... as GDNF, promote the survival of the neurons; however, clinical tests ... the Max Planck Institute of Neurobiology in Martinsried and their colleagues ...
... year around 11 million people suffer severe burns. The resulting ... results in lifelong scars. What is needed to reduce this ... Only a very limited area of skin can be removed ... new wounds. Besides conventional skin grafting, another option is to ...
... synthetic biology will be established in Bristol, Nottingham ... from the Biotechnology and Biological Sciences Research Council ... Council (EPSRC). The 40M+ investment will be ... David Willetts tonight at a BBSRC event in ...
Cached Biology News:Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3Blood and lymphatic capillaries grown for the first time in the lab 2UK establishes 3 new synthetic biology research centers 2
... products ATP-Free using Mo Bio luciferase assay. Mo ... service that will allow you to certify your ... and enable you to deliver them to your ... ATP detection limit is 3.5 x 10-12 /l, ...
... in Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, ... Germany) have collaborated to develop a fluorescence ... The DNAscope AT is based on ... AT automatically reads up to six ArrayTubes ...
... provides a comprehensive kinase analysis service ... (PKS) peptide microarrays synthesized on Paraflo ... profiling, quantitative measurement of kinase kinetic ... comprehensive service includes preparation of your ...
... The JNK (c-Jun NH2-terminal kinase) signal ... identified MAP kinase pathways in mammals. ... to environmental stress, is associated with ... and is implicated in the immune ...
Biology Products: